Therapeutic potential of [ < sup > 177 < /sup > Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment
CONCLUSION: The findings suggest that [177Lu]Lu-DOTAGA.FAPi dimer therapy is well-tolerated, safe, and effective for treating end-stage metastatic breast cancer patients. [177Lu]Lu-DOTAGA.FAPi dimer treatment demonstrated promising efficacy in patients with advanced breast cancer, as indicated by high disease control rates, favorable response outcomes, and acceptable safety profile. Further research and longer follow-up are warranted to assess long-term outcomes and validate these findings.PMID:37932560 | DOI:10.1007/s00259-023-06482-z (Source: Molecular Medicine)
Source: Molecular Medicine - November 6, 2023 Category: Molecular Biology Authors: Madhav P Yadav Sanjana Ballal Marcel Martin Frank Roesch Swayamjeet Satapathy Euy S Moon Madhavi Tripathi Ajay Gogia Chandrasekhar Bal Source Type: research
Therapeutic potential of [ < sup > 177 < /sup > Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment
CONCLUSION: The findings suggest that [177Lu]Lu-DOTAGA.FAPi dimer therapy is well-tolerated, safe, and effective for treating end-stage metastatic breast cancer patients. [177Lu]Lu-DOTAGA.FAPi dimer treatment demonstrated promising efficacy in patients with advanced breast cancer, as indicated by high disease control rates, favorable response outcomes, and acceptable safety profile. Further research and longer follow-up are warranted to assess long-term outcomes and validate these findings.PMID:37932560 | DOI:10.1007/s00259-023-06482-z (Source: Cancer Control)
Source: Cancer Control - November 6, 2023 Category: Cancer & Oncology Authors: Madhav P Yadav Sanjana Ballal Marcel Martin Frank Roesch Swayamjeet Satapathy Euy S Moon Madhavi Tripathi Ajay Gogia Chandrasekhar Bal Source Type: research
Therapeutic potential of [ < sup > 177 < /sup > Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment
CONCLUSION: The findings suggest that [177Lu]Lu-DOTAGA.FAPi dimer therapy is well-tolerated, safe, and effective for treating end-stage metastatic breast cancer patients. [177Lu]Lu-DOTAGA.FAPi dimer treatment demonstrated promising efficacy in patients with advanced breast cancer, as indicated by high disease control rates, favorable response outcomes, and acceptable safety profile. Further research and longer follow-up are warranted to assess long-term outcomes and validate these findings.PMID:37932560 | DOI:10.1007/s00259-023-06482-z (Source: Molecular Medicine)
Source: Molecular Medicine - November 6, 2023 Category: Molecular Biology Authors: Madhav P Yadav Sanjana Ballal Marcel Martin Frank Roesch Swayamjeet Satapathy Euy S Moon Madhavi Tripathi Ajay Gogia Chandrasekhar Bal Source Type: research
The uncharted role of HER2 mutant alleles in breast cancer
Oncotarget. 2023 Oct 31;14:904-907. doi: 10.18632/oncotarget.28489.ABSTRACTSomatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. Herein, we discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive d...
Source: Oncotarget - November 3, 2023 Category: Cancer & Oncology Authors: Rashi Kalra Bora Lim Matthew J Ellis Shyam M Kavuri Source Type: research
The uncharted role of HER2 mutant alleles in breast cancer
Oncotarget. 2023 Oct 31;14:904-907. doi: 10.18632/oncotarget.28489.ABSTRACTSomatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. Herein, we discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive d...
Source: Oncotarget - November 3, 2023 Category: Cancer & Oncology Authors: Rashi Kalra Bora Lim Matthew J Ellis Shyam M Kavuri Source Type: research
